Skip to main content
    G

    Gyre Therapeutics Inc. (GYRE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.39
    +0.08 (+1.86%)

    Market Cap: $471.74M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Gyre Therapeutics Inc. (GYRE) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Gyre Therapeutics (GYRE) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Gyre Therapeutics reported EPS of $0.04, above the -$0.15 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    44%(7/16)
    Avg Surprise
    -29.95%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.13
    Range-$0.20 - -$0.05
    5 analysts
    Revenue Consensus
    $30.21M
    Range$24.93M - $35.49M
    5 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.17
    Range-$0.17 - -$0.17
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago$0.00n/a
    Current-$0.17
    Revenue Consensus
    $22.50M
    Range$22.50M - $22.50M
    1 analysts

    Next Report

    GYRE has an expected report date of Mar 10, 2027.

    Earnings History

    Of the 16 quarters below that had an estimate, GYRE beat 7 and missed 9. Revenue for the quarter ended Sep 30, 2026 was $32.93M, up 0.7% from $32.69M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.04-$0.15-$0.19 - -$0.06+126.67%Beat+33.3%31 up, 2 downNov 5, 2026$32.93M
    Jun 30, 2026-$0.12-$0.08-$0.09 - $0.00-50.00%Miss-5554.5%30 up, 1 downAug 7, 2026$29.11M
    Mar 31, 2026-$0.10-$0.07-$0.11 - -$0.04-42.86%Miss-2425.6%30 up, 2 downMay 7, 2026$22.52M
    Dec 31, 2025$0.05$0.05N/A+0.21%BeatN/A10 up, 1 downMar 12, 2026$37.20M
    Sep 30, 2025$0.03-$0.02-$0.02 - -$0.02+250.00%Beat+129.0%10 up, 0 downNov 7, 2025$32.69M
    Jun 30, 2025$0.00$0.03N/A-92.67%Miss-93.5%N/A0 up, 0 downAug 11, 2025$29.73M
    Mar 31, 2025$0.00$0.03N/A-85.67%Miss-86.4%N/A0 up, 0 downMay 9, 2025$22.06M
    Dec 31, 2024$0.00$0.04N/A-102.75%MissN/AN/A0 up, 0 downMar 17, 2025$27.87M
    Sep 30, 2024$0.01N/AN/AN/AN/AN/AN/AN/ANov 13, 2024$25.49M
    Jun 30, 2024$0.03N/AN/AN/AN/AN/AN/AN/AAug 13, 2024$25.23M
    Mar 31, 2024$0.03N/AN/AN/AN/A-78.9%N/A0 up, 0 downMay 9, 2024$27.17M
    Dec 31, 2023Not reported-$0.60N/AN/ANot reportedN/AN/A0 up, 0 downMar 26, 2024$27.15M
    Sep 30, 2023-$1.05-$0.75N/A-40.00%MissN/AN/AN/AOct 26, 2023$32.04M
    Jun 30, 2023-$1.05-$1.05N/A-0.05%Miss-104.3%N/AN/AAug 14, 2023$29.33M
    Mar 31, 2023$0.15-$0.07N/A+314.29%BeatN/AN/AN/AMay 15, 2023$24.93M
    Dec 31, 2022-$19.05-$0.11N/AN/AN/AN/AN/AN/AMar 30, 2023$101.50M
    Sep 30, 2022-$2.40-$0.10N/AN/AN/AN/AN/AN/ANov 14, 2022N/A
    Jun 30, 2022$24.60-$0.25N/AN/AN/AN/AN/AN/AAug 15, 2022N/A
    Mar 31, 2022-$6.90-$0.46N/AN/AN/AN/AN/AN/AMay 9, 2022$794000
    Dec 31, 2021-$9.75-$0.59N/AN/AN/AN/AN/AN/AMar 31, 2022$2.44M
    Sep 30, 2021-$12.00-$0.66N/AN/AN/AN/AN/AN/ANov 12, 2021$2.30M
    Jun 30, 2021-$9.60-$0.70N/AN/AN/AN/AN/AN/AAug 5, 2021$1.13M
    Mar 31, 2021-$11.85-$0.58N/AN/AN/AN/AN/AN/AMay 6, 2021$1.47M
    Dec 31, 2020-$12.90-$0.86N/AN/AN/AN/AN/AN/AMar 4, 2021$1.17M
    Sep 30, 2020-$10.95-$0.81N/AN/AN/AN/AN/AN/ANov 5, 2020$1.75M
    Jun 30, 2020-$14.40-$0.86N/AN/AN/AN/AN/AN/AAug 6, 2020$1.66M
    Mar 31, 2020-$4.20-$0.37N/AN/AN/AN/AN/AN/AMay 11, 2020$16.37M
    Dec 31, 2019-$18.45$0.17N/AN/AN/AN/AN/AN/AFeb 20, 2020N/A
    Sep 30, 2019-$15.90-$1.16N/AN/AN/AN/AN/AN/ANov 7, 2019N/A
    Jun 30, 2019-$17.25-$1.11N/AN/AN/AN/AN/AN/AAug 1, 2019N/A
    Mar 31, 2019-$18.90-$1.08N/AN/AN/AN/AN/AN/AMay 2, 2019N/A
    Dec 31, 2018-$13.65-$0.75N/AN/AN/AN/AN/AN/AMar 8, 2019N/A
    Sep 30, 2018-$9.60-$0.59N/AN/AN/AN/AN/AN/ANov 1, 2018N/A
    Jun 30, 2018-$8.10-$0.62N/AN/AN/AN/AN/AN/AAug 2, 2018N/A
    Mar 31, 2018-$8.40-$0.92N/A-813.04%MissN/AN/AN/AMay 3, 2018$6000
    Dec 31, 2017-$1.25-$1.53N/A+18.30%BeatN/AN/AN/AMar 19, 2018$318000
    Sep 30, 2017-$20.10-$1.32N/AN/AN/AN/AN/AN/ANov 2, 2017$318000
    Jun 30, 2017-$1.52-$1.46N/A-4.11%MissN/AN/AN/AAug 3, 2017$111000
    Mar 31, 2017-$4.57-$6.10N/A+25.08%BeatN/AN/AN/AMay 11, 2017$271000
    Dec 31, 2016-$4.65-$5.63N/A+17.41%BeatN/AN/AN/AMar 8, 2017$72000
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.08, within 4 cents of the year before. It was -$165.78 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.08N/A
    Dec 31, 2024$0.08N/A
    Dec 31, 2023-$1.95N/A
    Dec 31, 2022-$3.75N/A
    Dec 31, 2021-$43.20N/A
    Dec 31, 2020-$42.45N/A
    Dec 31, 2019-$70.50N/A
    Dec 31, 2018-$39.75N/A
    Dec 31, 2017-$27.44N/A
    Dec 31, 2016-$165.78N/A

    Frequently Asked Questions About GYRE

    When is Gyre Therapeutics's next earnings date?

    Gyre Therapeutics's next earnings report is expected for Mar 10, 2027.

    Did GYRE beat earnings estimates last quarter?

    Yes. Gyre Therapeutics reported EPS of $0.04 for the quarter ended Sep 30, 2026, above the -$0.15 estimate, a 126.67% surprise.

    What EPS do analysts expect from GYRE next quarter?

    The consensus EPS estimate for Gyre Therapeutics for the quarter ending Dec 31, 2026 is -$0.13 from 5 analysts, with estimates from -$0.20 to -$0.05.

    How often does GYRE beat earnings estimates?

    Gyre Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of +0.37%.